{"id":"NCT01623310","sponsor":"Optinose US Inc.","briefTitle":"12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device","officialTitle":"12-Month OL Evaluating the Safety of Intranasal Administration Fluticasone BID Using OptiNose Device in Subjects With CS With or Without Nasal Polyps","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2015-08","completion":"2015-10","firstPosted":"2012-06-19","resultsPosted":"2018-01-24","lastUpdate":"2018-01-24"},"enrollment":223,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nasal Polyps"],"interventions":[{"type":"DRUG","name":"Fluticasone Propionate","otherNames":["OPN-375"]}],"arms":[{"label":"OPN-375 400 μg BID","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The duration of each subject's participation is approximately 53 weeks.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"12 Months","effectByArm":[{"arm":"OPN-375 400 μg","deltaMin":169,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":26},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":223},"commonTop":["Nasal mucosal disorder","Epistaxis Identified via Nasal Endoscopy","Nasal Septum Disorder","Acute Sinusitis","Spontaneously Reported Epistaxis"]}}